Yulong Eco-Materials Ltd. (YECO)

Overview

EV Biologics, Inc. is a pioneering biotechnology company actively engaged in the commercial development of extracellular vesicles (EVs), which serve as novel biological modalities for both diagnostics and therapeutics. Originally known as Yulong Eco-Materials Limited, the company underwent a significant rebranding in August 2020, adopting its current name to better reflect its focus and ambitions in the biotechnology arena. Founded in 2011 and based in Cheyenne, Wyoming, EV Biologics is at the forefront of leveraging its proprietary multifunctional EV platform to revolutionize the development of vaccines, therapeutics, and potential cures. Beyond its innovative research in biomedicine, the company is also expanding its horizons into the cosmetic and biopharmaceutical sectors, emphasizing its commitment to developing advanced human mesenchymal and other stem cell and cell-derived products.

Products and Services

• Extracellular Vesicles (EVs) for Diagnostics and Therapeutics

  EV Biologics centers its core activities around the exploitation of extracellular vesicles. These nanosized particles are harnessed for their potential in diagnosing a wide array of diseases, as well as their capabilities as therapeutic agents. By tapping into the natural biological processes, EVs offer a promising and innovative approach to precision medicine.

• Vaccine Development

  Utilizing its proprietary EV platform, the company is heavily invested in the advancement of vaccines. The focus is on creating more effective, safer, and targeted vaccine solutions that can cater to a wide range of diseases, embodying a new era in immunization practices.

• Therapeutics and Cures

  At the heart of EV Biologics' operations is the ambition to pioneer novel therapeutic modalities. Through their multifunctional EV platform, they aim to develop effective treatments and potential cures for complex diseases, leveraging the natural therapeutic properties of extracellular vesicles to combat illness at its root.

• Human Mesenchymal and Other Stem Cell Products

  Beyond its activities in the medical and pharmaceutical domains, EV Biologics is also exploring the market potential of human mesenchymal and other stem cell, and cell-derived products, particularly within the cosmetic and biopharmaceutical spaces. This venture showcases the company’s commitment to harnessing cellular and molecular biology to meet a broad spectrum of human health needs, from aesthetic improvements to medical treatments.